Rezolute (RZLT) Shares Outstanding (Diluted Average) (2013 - 2026)
Rezolute recorded quarterly Shares Outstanding (Diluted Average) of $103.7 million in Q1 2026, little changed quarter-over-quarter from $103.7 million in Q4 2025, and up 48.1% year-over-year from $70.0 million in Q1 2025.
Rezolute's Shares Outstanding (Diluted Average) history runs 9 years deep, the most recent figure standing at $103.7 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 48.1% year-over-year to $103.7 million; the TTM figure through Mar 2026 stood at $103.7 million (up 48.1% YoY), while the FY2025 annual figure was $76.0 million, up 47.67% from the prior year.
- Shares Outstanding (Diluted Average) came in at $103.7 million for Q1 2026 at Rezolute, roughly flat from $103.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $103.7 million in Q1 2026 to a low of $13.7 million in Q1 2022.
- A 5-year average of $61.1 million and a median of $51.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) soared 493.54% in 2022 and increased 0.19% in 2024, its largest moves.
- Rezolute's Shares Outstanding (Diluted Average) stood at $51.0 million in 2022, then gained by 0.86% to $51.4 million in 2023, then soared by 36.05% to $69.9 million in 2024, then jumped by 48.25% to $103.7 million in 2025, then rose by 0.03% to $103.7 million in 2026.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $103.7 million, $103.7 million, and $103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 103.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.71 Mn |
| Dec 31, 2025 | 103.69 Mn |
| Sep 30, 2025 | 103.42 Mn |
| Jun 30, 2025 | 76.00 Mn |
| Mar 31, 2025 | 70.03 Mn |
| Dec 31, 2024 | 69.94 Mn |
| Sep 30, 2024 | 69.74 Mn |
| Jun 30, 2024 | 51.47 Mn |
| Mar 31, 2024 | 51.21 Mn |
| Dec 31, 2023 | 51.41 Mn |
| Sep 30, 2023 | 51.41 Mn |
| Jun 30, 2023 | 51.19 Mn |
| Mar 31, 2023 | 51.11 Mn |
| Dec 31, 2022 | 50.97 Mn |
| Sep 30, 2022 | 50.53 Mn |
| Jun 30, 2022 | 19.49 Mn |
| Mar 31, 2022 | 13.75 Mn |
| Dec 31, 2021 | 15.68 Mn |
| Sep 30, 2021 | 8.51 Mn |
| Jun 30, 2021 | 7.67 Mn |
| Mar 31, 2021 | 7.45 Mn |
| Dec 31, 2020 | 8.05 Mn |
| Sep 30, 2020 | 5.87 Mn |
| Jun 30, 2014 | 9.38 Mn |
| Jun 30, 2013 | 6.20 Mn |